Form 4 for IMVT Immunovant, Inc.
Accepted 2021-08-04 00:00:00 ET · period of report 2021-08-03 · accession 0001764013-21-000068 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-08-04 | 2021-08-03 | IMVT | Salzmann Peter | CEO, Dir | A - Grant | $0.00 | +570.6K | 703.1K | +431% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-03 | A | A | 570,613 | $0.00 | 703,113 | D | — | — | (F1) Represents the number of shares underlying restricted stock units awards ("RSUs"). (F2) 37.5% of the RSUs will vest on January 1, 2022 and the remainder of the RSUs will vest on August 3, 2023, subject to the Reporting Person providing continuous service to the Issuer as of each such date. |